28 August 17 The Business Times by CHAI HUNG YIN
US-BASED life science company Thermo Fisher Scientific, which produces life science instruments in Singapore for the global market, has expanded its presence in Asia-Pacific and emerging markets in the last few years to more than 20 per cent of the total global revenue.
Ravi Shastri, Thermo Fisher Scientific's vice-president and general manager of South-east Asia and Taiwan, said: "This demonstrates that our size and scale in the region is a clear competitive advantage."
The US-listed company reported global revenues of US$18.7 billion in 2016, and now employs more than 55,000 employees worldwide.
In Singapore, the company has a footprint of over 500,000 sq ft and employs over 1,200 employees, with teams in manufacturing, research and development (R&D), customer-facing applications and Asia-Pacific operations.
Singapore is one of the company's centres for excellence globally for instruments manufacturing, noted Mr Shastri.
He said: "Thermo Fisher continues to invest in and expand its manufacturing, R&D and commercial capabilities in Singapore in order to better serve customers in Asia-Pacific and globally from this important hub."
Thermo Fisher's first cloud-enabled scientific instrument was developed by its Singapore team and launched sometime in 2015, a major milestone for the company in the push to enhance lab productivity.
The Applied Biosystems QuantStudio 3 and 5 Real-Time PCR Systems allow users to remotely monitor their experimental runs and results in real-time through their mobile devices.
Said Mr Shastri: "On this single platform, they can also perform various forms of preliminary analysis with a suite of professional analytical tools at their disposal."
Over the years, the Singapore team has developed and launched many instrument models, including the Qubit 3.0 Fluorometer, the versatile ProFlex PCR system, the compact SimpliAmp thermal cycler and, most recently, the E-Gel Power Snap Electrophoresis Device and Power Snap Camera, said Mr Shastri.
"The company employs a 'huband-spoke' strategy where Singapore-based design firms, universities and research institutions play significant roles in supporting the development of instrument platforms."
Key partners include publicly-funded research institutions at A*Star, universities and academic clinical centres, said Mr Shastri.
"With research institutions and universities, the projects cover a wide range of areas including synthetic biology, cancer biomarkers, diagnostics, and cell lines optimisation for biologics drug production."
Playing instrumental role in the world's life science sector
S'pore unit makes 95% of global leader's products